Dr Peter Sasieni speaks to ecancer about results from the large NHS-Galleri trial evaluating a multi-cancer early detection (MCED) blood test in asymptomatic individuals aged 50–79 show meaningful shifts in how cancers are detected.

While the study did not meet its primary endpoint of reducing stage III/IV cancers overall, MCED screening led to a 14% reduction in stage IV cancers and a 16% increase in early-stage (I/II) diagnoses over three years.

Dr Sasieni highlights that these findings suggest that integrating MCED blood testing into routine screening has the potential play a significant role in shifting cancer detection earlier and reducing late-stage disease burden at the population level.

Health services such as the UK's NHS will now examine the cost commpared to effectiveness.